Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-06-18

The histone H3.3 variant in brain cancer pathogenesis

Objetivo

Epigenetic reprogramming is a hallmark of brain cancer. Remarkably, driver mutations of the histone H3.3 variant and its loading machinery have been recently found in paediatric glioblastoma multiforme (GBM), a devastating neoplasm originating from transformed neural precursors. Thus, the very basic building blocks of chromatin can be mutated in cancer.
The present challenge is to define at which level altered H3.3 loading influences GBM pathogenesis and provide clues into the underlying mechanisms. Based on work from our group and others, we hypothesise that alterations of H3.3 function/deposition would lead to epigenetic changes, deregulated transcription at bivalent loci and other genomic regions, and alterations of telomere maintenance mechanisms, in turn contributing to tumourigenesis.

The main objectives of this proposal are to:
1. Examine the impact of H3.3 mutations on brain cancer pathogenesis, by determining the effect of mutant H3.3 expression on neural precursor cell transformation (A), and tumour maintenance (B).
2. Define the molecular changes caused by incorporation of H3.3 mutants into the genome and their involvement in tumourigenesis, by A. determining the genome-wide distribution of WT and mutant H3.3 proteins, B. identifying mutant H3.3-driven transcriptional and epigenetic changes, C. defining effects on telomere maintenance mechanisms, and D. connecting mutant H3.3-driven molecular changes to the biological phenotypes.

The discovery of mutations in histones and their loading machinery represents a paradigm change in the field of cancer epigenetics. We anticipate this study to provide key insights into the role of these alterations in chromatin regulation and cancer pathogenesis. More broadly, this work will increase our understanding of the fundamental mechanisms governing chromatin modification in mammalian cells.

Convocatoria de propuestas

ERC-2013-CoG
Consulte otros proyectos de esta convocatoria

Régimen de financiación

ERC-CG - ERC Consolidator Grants

Institución de acogida

DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV
Aportación de la UE
€ 728 419,47
Dirección
VENUSBERG-CAMPUS 1/99
53127 Bonn
Alemania

Ver en el mapa

Región
Nordrhein-Westfalen Köln Bonn, Kreisfreie Stadt
Tipo de actividad
Research Organisations
Investigador principal
Paolo Salomoni (Prof.)
Contacto administrativo
Annette Schwarzenburg (Ms.)
Enlaces
Coste total
Sin datos

Beneficiarios (2)